Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)

Trial Profile

Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Dacarbazine; Paclitaxel; Temozolomide
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-002
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Jun 2018 Planned End Date changed from 2 Jul 2018 to 31 Jan 2019.
    • 11 Jun 2018 Results of a retrospective analysis from KEYNOTE-002, KEYNOTE-010 and KEYNOTE-024 studies published in the Clinical Cancer Research
    • 26 Sep 2017 Primary endpoint (Overall Survival (OS)) for both Arm 1-Pembrolizumab 2 mg/kg versus investigator-choice chemotherapy and Arm 2 -Pembrolizumab 10 mg/kg versus investigator-choice chemotherapy has not been met, according to results published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top